Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Update on GSK744 and Monthly HIV Treatment or PrEP

March 14, 2014

For months, we've been excited about emerging data regarding GSK744 (also known as "744"), an investigational integrase inhibitor, close cousin of dolutegravir (Tivicay, DTG), with the potential for once-monthly injection dosing and promise in pre-exposure prophylaxis (PrEP) -- at least in rectally-exposed monkeys. Indeed, adherence concerns remain prominent in both of these therapeutic areas, concerns that could be readily addressed by directly observed, injectable treatments.

Data presented at CROI 2014 continued to fuel this fire. First, investigators showed that once-monthly injections of 744 provided 100% protection (in monkeys) from repeated intravaginal challenge from SHIV.

View Full Article


  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

 
See Also
More on HIV Medications
Other Integrase Inhibitors
Advertisement:
Find out how a Walgreens specially trained pharmacist can help you

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Tools
 

Advertisement